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Abstract
Background: Internet-based cognitive behavior therapy (ICBT) has shown promising effects in the treatment of
irritable bowel syndrome (IBS). However, to date no study has used a design where participants have been
sampled solely from a clinical population. We aimed to investigate the acceptability, effectiveness, and cost-
effectiveness of ICBT for IBS using a consecutively recruited sample from a gastroenterological clinic.
Methods: Sixty-one patients were randomized to 10 weeks of ICBT (n = 30) or a waiting list control (n = 31). The
ICBT was guided by an online therapist and emphasized acceptance of symptoms through exposure and
mindfulness training. Severity of IBS symptoms was measured with the Gastrointestinal symptom rating scale - IBS
version (GSRS-IBS). Patients in both groups were assessed at pre- and post-treatment while only the ICBT group
was assessed 12 months after treatment completion. Health economic data were also gathered at all assessment
points and analyzed using bootstrap sampling.
Results: Fifty of 61 patients (82%) completed the post-treatment assessment and 20 of 30 patients (67%) in the
ICBT group were assessed at 12-month follow-up. The ICBT group demonstrated significantly (p < .001) larger
improvements on the IBS-related outcome scales than the waiting list group. The between group effect size on
GSRS-IBS was Cohen’s d = 0.77 (95% CI: 0.19-1.34). Similar effects were noted on measures of quality of life and IBS-
related fear and avoidance behaviors. Improvements in the ICBT group were maintained at 12-month follow-up.
The ICBT condition was found to be more cost-effective than the waiting list, with an 87% chance of leading to
reduced societal costs combined with clinical effectiveness. The cost-effectiveness was sustained over the 12-
month period.
Conclusions: ICBT proved to be a cost-effective treatment when delivered to a sample recruited from a
gastroenterological clinic. However, many of the included patients dropped out of the study and the overall
treatment effects were smaller than previous studies with referred and self-referred samples. ICBT may therefore be
acceptable and effective for only a subset of clinical patients. Study dropout seemed to be associated with severe
symptoms and large impairment. Objective and empirically validated criteria to select which patients to offer ICBT
should be developed.
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Irritable bowel syndrome (IBS) is a functional bowel
disorder characterized by recurring symptoms of
abdominal pain or discomfort, accompanied by diar-
rhea or constipation [1]. For a majority of the affected,
IBS is chronic and leads to impaired quality of life
[2-4]. Compared to normal controls, IBS-patients are
about three times more likely to be absent from work
[5] and they utilize health care resources at almost
double the cost [6]. Given the high prevalence of IBS,
ranging between 5 and 11% [7], the societal costs of
IBS are substantial [8].
Cognitive behavior therapy (CBT) is considered the
most well-studied psychological treatment for IBS [9],
but one limitation is that CBT is rarely available in rou-
tine care of IBS [10]. Several factors contribute to this,
e.g. the lack of trained therapists, high costs of deliver-
ing the treatment, and the practical difficulties for
patients of scheduling weekly visits at a clinic. To
increase the availability of CBT for IBS, our research
group has conducted two studies investigating CBT for
IBS where participants had therapist contact via the
internet (ICBT). In ICBT, patients learn about the treat-
ment interventions by reading self-help texts that con-
tain both educational material and instructions on how
to perform the exercises that constitute the treatment.
The general principle is that the treatment should
reflect face-to-face therapy in terms of content, but
using an online therapist to guide the participants
through the course of the treatment. The format allows
for large patient volumes to be treated and an increasing
number of controlled studies indicate that for common
psychiatric disorders ICBT is as effective as face-to-face
delivered treatment [11-13]. In our trials of ICBT for
IBS the treatment was found to be significantly more
effective than a waiting list control condition [14] and a
treatment based on stress and symptom management
[15]. A follow-up study also showed maintenance of
improvements over a 15-18 months period [16] and that
the treatment was associated with considerable long-
term societal cost-savings [17]. The treatment, which is
based on exposure to IBS symptoms and mindfulness
exercises, has also been evaluated in an uncontrolled
pilot study using a group treatment format, showing
similar effects [18].
These results indicate that an effective treatment can
now be offered to a large number of IBS patients. How-
ever, the generalizability of our studies and other studies
investigating CBT for IBS with reduced therapist time
[19-22] is limited by the fact that study participants
have mostly been recruited by referral and self-referral.
It could be assumed that these methods of recruitment
result in samples of IBS patients who are more willing
and able to participate in a minimal contact therapy and
who are also more responsive to CBT in general.
In the present study we offered the ICBT that we have
previously evaluated with self-referred IBS patients
[14,15] to consecutively recruited patients at a gastroen-
terological outpatient clinic. Our aim was to investigate
the acceptability, effectiveness, and cost-effectiveness of
the treatment for a representative sample of tertiary care
IBS patients. Our primary hypothesis was that, com-
pared to a waiting list, ICBT would lead to greater
reductions in IBS-symptoms at the end of treatment.
We also hypothesized that ICBT would be superior to a
waiting list in terms of cost-effectiveness, improvement
in symptom-related anxiety, quality of life, and general
functioning. Additionally, the improvements gained
from treatment were hypothesized to be maintained 12
months after treatment.
Methods
This study is reported in accordance with the CON-
SORT statement for non-pharmacological trials [23] and
was approved by the regional ethics committee in Stock-
holm, Sweden.
Sample and recruitment
Power considerations
In our previous study of ICBT for IBS using a waiting
list control, we had a between-groups effect size
(Cohen’s d) of 1.21 (95% CI: 0.73-1.66) on the primary
outcome measure at post-treatment [14]. Based on the
lower limit of the confidence interval, we powered this
study to have an 85% chance to detect an effect size of
at least 0.80, comparing treatment to a waiting list, on
the primary outcome. This gave a sample of at least 30
participants per study condition.
Inclusion criteria
Participants were eligible for the study if they a) had
their first visit at the recruiting clinic and were diag-
nosed during the recruitment period, b) had IBS symp-
toms as their primary reason for consultation, c)
fulfilled Rome III-criteria for IBS [1], d) were between
18 and 65 years old, e) had no presence of current or
previous inflammatory bowel disease, and f) lived in
Stockholm County. Eligible patients were excluded if
they g) reported debut of IBS symptoms after 50 years
of age and were judged to require continued monitoring
at the clinic, h) suffered from such severe diarrhea that
IBS-symptom modifying drugs with psychotropic effects,
such as tricyclic antidepressants or selective serotonin
reuptake inhibitors, were judged to be the treatment of
choice, i) could not read or write Swedish j) did not
have access to the internet, k) were judged to be highly
unsuitable for ICBT for somatic or psychological
Ljótsson et al. BMC Gastroenterology 2011, 11:110
http://www.biomedcentral.com/1471-230X/11/110
Page 2 of 13reasons as assessed by the gastroenterologist, or l) were
not willing to participate in the study.
Recruitment procedure
All patients were consecutively recruited at a single gas-
troenterological clinic located in Stockholm, Sweden.
Patients came to the clinic by referral or by self-referral.
All patients who had their first visit at the clinic
between November 19, 2008, and May 13, 2009 were
eligible for the study. The recruitment ended in June 22,
2009, so the patients had to have been diagnosed before
that date to be included in the study. As our aim was to
recruit patients who attended a regular gastroenterologi-
cal clinic and minimize selection bias, no information
about the study was spread through advertisements or
to other caregivers in Stockholm. Four gastroenterolo-
gists with 10 to 30 years of specialist experience were
responsible for the recruitment. After diagnosing a
patient with IBS and confirming eligibility criteria the
gastroenterologist informed patients about the study.
Patients who were willing to participate signed a written
consent form. Some patients were contacted by tele-
phone and offered to participate in the study. Reasons
for telephone contact could be that the patient did not
return for a second visit to receive their diagnosis, that
he or she could not immediately decide whether to par-
ticipate in the study, or that the gastroenterologist had
omitted to inform the patient about the study during
the visit at the clinic. Patients that agreed to participate
in the study via telephone signed the written consent
form at the ensuing psychiatric assessment (see below).
All included patients were given standardized informa-
tion about IBS and basic dietary and lifestyle advice on
how to manage their IBS (i.e., treatment as usual). If
appropriate they were also prescribed medication and/or
given information about over-the-counter drugs. To
ensure that this basic IBS management would have had
its effect before patients begun their participation in the
study, the pre-treatment assessment was conducted at
least one month after inclusion.
After the recruitment period had ended, the study’s
coordinating gastroenterologist (P.L.) reviewed all visits
at the clinic during the recruitment period to check if
all eligible patients had been considered for the study.
The clinic’s computerized medical record system
allowed us to filter out all patients who did not fulfill
eligibility criteria. A total of 456 patients had their first
visit at the clinic during the recruitment period, and 131
of these were eligible according to their medical record.
However, for 16 eligible patients there were no indica-
tions that they had been considered for the study and it
could not be determined why they had not been
included. Upon reviewing the records of these 16
patients, no obvious biases were found that could
explain these breaches of the study protocol. Of the 115
patients that were considered for the study, 35 were
excluded based on criteria g-j (reasons for exclusion are
detailed in Figure 1), 5 patients could not be reached by
telephone within the recruitment period, and 75 were
included in the study. Of the 75 patients that were
included at the clinic, 14 withdrew in the period
between inclusion and pre-treatment assessment (rea-
sons for withdrawal are given in Figure 1) and 61 were
randomized. Demographics for the randomized partici-
pants are given in Table 1 and participant flow through
the study is detailed in Figure 1.
Randomization
Randomization was performed by sending a list of anon-
ymous participant identification numbers to one of the
Firstvisitattheclinic
(n=456)
Eligibleforstudy(n=131)
Notincluded(n=56)
Doctor’somission:16
Declinedparticipation:12
Severediarrhea:11
Unreachable:5
Psychiatricreasons:2
Somaticreasons:2
Poorlanguageskills:4
Nointernetaccess:3
Symptomdebutafter50:1
Includedinstudy(n=75) Droppedoutbefore
randomization(n=14)
Symptomimprovement:3
ICBTnotsuitable:3
Practicalreasons:3
Noreasongiven:5 PreͲtreatment
assessmentand
randomization(n=61)
AllocatedtoICBT
(n=30)
Allocatedtowaiting
list(n=31)
LosttofollowͲup:
Didnotcomplete
postͲtreatment
assessment(n=7),
12ͲmonthfollowͲup
assessment(n=10)
LosttofollowͲup:
Didnotcomplete
postͲtreatment
assessment(n=4)
MixedmodelspreͲ
topostͲtreatment:
analyzed(n=30)
CostͲeffectiveness:
analyzed(n=30)
MixedmodelspostͲ
treatmenttofollowͲ
up:analyzed(n=24)
MixedmodelspreͲ
topostͲtreatment:
analyzed(n=31)
CostͲeffectiveness:
analyzed(n=31)
Figure 1 Participant flow through the trial.
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Page 3 of 13co-authors (E.H.) who had no involvement in the
recruitment, administration, assessment, or treatment of
the patients. A true random number service (http://
www.random.org) was used to allocate the participants
to either ICBT or waiting list, using simple randomiza-
tion with no restrictions. After randomization the anon-
ymous participant identification numbers were returned
together with their allocation to the first author who
coordinated the study (B.L.). Since all outcomes that
were waiting list controlled were self-assessed, there was
no concealment of allocation.
Treatment condition
The ICBT in this study is based on a treatment protocol
that has been evaluated previously in group format and
delivered via internet [14,15,18]. The treatment aims to
break the vicious cycle between avoidance behaviors,
symptom severity, and functional impairment. It is
based on the proposed central role of symptom-related
fear and associated avoidance behaviors in IBS [24].
Since fear alters motility [25] and directs attention
towards threat [26], the association between symptom-
related stimuli and fear constitutes a solid foundation
for positive feedback loops between stress and IBS
symptoms, as well as an increased awareness of symp-
toms. Use of avoidance behaviors to cope with this fear
may also lead to long-term aggravation of symptoms
because of increased general stress and strengthened
negative valence of symptoms. Several studies have con-
firmed the impact of symptom-related fear and
avoidance behaviors on symptom severity and quality of
life in IBS [24,27-30].
In comparison to other CBT-protocols for IBS, the
main unique feature of the CBT in this study is its strict
reliance on acceptance of IBS symptoms and related
cognitions and feelings through exposure exercises com-
bined with mindful awareness. It is inspired by the
“third wave” of CBT that includes treatments such as
acceptance and commitment therapy (ACT) and dialec-
tic behavior therapy (DBT)[31]. In this treatment, expo-
sure is proposed to serve two purposes. Similarly to how
exposure has been used in other studies of CBT for IBS
[21,32,33], it will result in long-term extinction of the
fear response to IBS-related stimuli, leading to reduction
in symptoms. But in accordance with reasoning within
ACT [31,34], exposure also serves to increase behavioral
flexibility in the presence of IBS-related stimuli, while
being aware of and accepting the feelings elicited by the
stimuli. By practicing a behavioral repertoire that is not
influenced by fluctuations in IBS symptoms and mood,
patients will perceive symptoms as less threatening to
their ability to function.
The treatment also includes mindfulness training.
Mindfulness-based stress reduction for IBS has been
evaluated in two recent studies [35,36] with mixed
results. While patients in both studies experienced
improvement in quality of life only one of the studies
demonstrated effects on IBS symptoms [36]. Mindful-
ness training in this treatment does not serve to
decrease stress but rather to practice acceptance of aver-
sive inner experiences while engaging in flexible and
more functional behavioral responses to these experi-
ences, similarly to how it is used in ACT and DBT
[37,38].
The treatment in this study lasted for 10 weeks and
was divided into five successive steps. The content of
each step is presented in Table 2. Patients had to report
that they had worked through a treatment step to get
access to the next. Patients were encouraged to work
through steps 1-4 during the first half of the treatment
and to spend the latter half of the treatment on step 5,
in which exposure exercises were introduced. The num-
ber of patients in the treatment group reaching each
step is presented in Table 2. During treatment, patients
also had access to an online closed discussion forum
where they could discuss their treatment with each
other.
Three clinical psychologists managed the online thera-
peutic contact in this study. Therapist contact was
usually initiated by the participants who were encour-
aged to send at least one message per week about their
work with the treatment to their therapist. Patients were
given feedback within 1-2 days after they had posted a
m e s s a g e .O na v e r a g e ,p a t i e n t ss e n t8 . 2( S D=4 . 7 ,r a n g e
Table 1 Sample characteristics
Total
sample
(n = 61)
Treatment
group
(n = 30)
Waiting
list
(n = 31)
% Female 74% 77% 71%
Age (SD) 34.9 (11.3) 33.5 (11.2) 36.3 (11.3)
Years with IBS (SD) 11.5 (11.8) 11.7 (12.7) 11.3 (11.1)
IBS subtype %
Constipation 21% 20% 23%
Diarrhea 30% 27% 32%
Mixed 49% 53% 45%
Married % 81% 77% 84%
Education %
Elementary
school
5% 7% 3%
High school 30% 33% 26%
University degree 62% 60% 65%
Doctoral degree 3% 0% 7%
Employment status %
Employed 79% 73% 84%
Unemployed 3% 7% 0%
Student 15% 17% 13%
Retired 3% 3% 3%
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Page 4 of 130-18) messages to their therapist and received 11.8 (SD
= 5.7, range 1-21) messages from their therapist. The
therapists spent a weekly mean of 7.3 minutes (SD =
5.2, range 0-24.5) per patient. Three types of feedback
were generally given by the online therapists: 1) Correc-
tive psychoeducational information if the patient’s
answers indicated that he/she had not fully grasped the
rationale for the treatment. 2) General support to main-
tain or increase the intensity of the patient’sw o r kw i t h
the treatment. 3) Guidance on how to perform and eval-
uate the exercises prescribed by the treatment.
Waiting list condition
Patients randomized to waiting list were crossed over to
treatment after the post-treatment assessment was con-
cluded. During the waiting list period these patients
were also offered the opportunity to communicate with
each other using an online closed discussion forum. The
discussion forum was included as a basic control for the
effects of weekly activity and attention. Online discus-
sion forums have been shown to alleviate distress asso-
ciated with breast cancer [39]. However, there was
almost no discussion forum activity in the waiting list
condition.
Data collection
All measures were administered online, a method which
has been shown to be reliable and as valid as traditional
paper-and-pencil administration [40,41]. The outcome
measures were assessed at three time points; pre-treat-
ment, post-treatment, and 12-month follow-up (ICBT
only). Additional data that are not part of this report
were also collected. Waiting list group participants
completed assessments immediately after and 12 months
after having been crossed over to and finishing treat-
ment. Psychiatric assessments of all patients were also
conducted before randomization and at 12-month fol-
low-up. This psychiatric assessment, which was per-
formed during a visit at a psychiatric clinic in
Stockholm, was not part of the inclusion process and
did not guide the treatment intervention.
Primary outcome
The primary outcome measure of the study was the
Gastrointestinal Symptom Rating Scale-IBS version
(GSRS-IBS) [42]. The GSRS-IBS is a version of the Gas-
trointestinal Symptom Rating Scale [43] extended with
questions about Rome I-criteria for IBS. The GSRS-IBS
comprises 13 items covering severity of gastrointestinal
symptoms, including pain, bloating, diarrhea, constipa-
tion, and satiety. Each item is scored between 1 (no dis-
comfort at all) and 7 (very severe discomfort), rendering
a total score between 13 and 91. The GSRS-IBS has
demonstrated adequate psychometric properties for the
different symptoms that are assessed, with an internal
consistency (Chronbach’s a)r a n g i n gb e t w e e n. 7 4a n d
.85 [42]. Since IBS symptoms are known to vary consid-
erably over time [44], the mean score of four weekly
assessments of GSRS-IBS was used to get reliable esti-
mates of the participants’ symptom levels at each assess-
ment point.
Secondary outcomes
Health economic data were collected using the Trimbos
and Institute of Medical Technology Assessment Cost
Questionnaire for Psychiatry (TIC-P) [45]. This
Table 2 Description of the treatment steps and number of patients reaching each step
Step Contents #o f
patients
1 Introduction to the treatment and two mindfulness exercises. 1. A 15-minute exercises during which the patient observes and
labels inner and outer experiences (practiced once daily). 2. A 20 second exercise that brings the patient into immediate
awareness of current thoughts, GI symptoms, feelings, and behavioral impulses (practiced several times daily).
7(23%)
2 Explanation of a psychological model of IBS. The learning of symptom-related fear through negative experiences of symptoms.
The effect of anxiety on gastrointestinal functioning and how it increases awareness of threatening stimuli - specifically IBS-
related stimuli.
6 (7%)
3 The role of negative thoughts in exacerbating IBS-related fear. A mindful and accepting stance towards negative thoughts and
experiences is proposed as an alternative to attempts to control these experiences.
3 (10%)
4 Explanation of how IBS-related avoidance and control behaviors maintain the fear of awareness of IBS-symptoms. Patients record
their own IBS-related behaviors.
5 (17%)
5 Behavior change and exposure, chiefly divided into three categories. 1) Reduction or removal of behaviors that serve to control
symptoms, such as repeated toilet visits, distraction, eating certain foods, resting, and taking unprescribed medications. 2)
Exposure to symptoms by engaging in activities that provoke symptoms, such as eating certain foods, physical activity, and
stressful situations. 3) Exposure to situations where symptoms are unwanted, such as attending a meeting when experiencing
abdominal pain or riding the bus with fear of losing control of the bowels. Instructions on how to use mindfulness during
exposure. By observing and labeling their environment during exposure, i.e., aversive, neutral, and positive internal and external
stimuli, patients will counter distraction from and suppression of thoughts and emotions. By attending to any impulses to flee
the situation or decrease the intensity of symptoms they will also be less inclined to act on these impulses.
In the last week of treatment all patients got access to a text that discussed how to handle relapses into avoidance behaviors
and how to maintain a widened behavioral repertoire.
13 (43%)
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Page 5 of 13questionnaire assesses monthly health care consumption
(direct medical costs) and time spent in other health
promoting activities (direct non-medical costs). The
TIC-P also assesses monthly sick-leave, reduced work
capacity at work and in the domestic realm, and
employment status (indirect non-medical costs).
The Irritable Bowel Syndrome Quality of Life Instru-
ment (IBS-QOL) [46] was used to assess the impact on
quality of life for patients with IBS, and includes
domains such as dysphoric thoughts, symptoms interfer-
ence with activity, food avoidance, and impact on rela-
tionships. The IBS-QOL consists of 34 items scored
between 1 and 6 and the total score is transformed to a
0 to 100 scale, where 0 represents minimum quality of
life and 100 represents maximum quality of life. The
IBS-QOL shows high internal consistency (Chronbach’s
a = .95) and test-retest reliability (r = .86) [46].
The Visceral Sensitivity Index (VSI) [28] measures the
cognitive, affective, attentional, and behavioral dimen-
sions relating to fear of IBS symptoms and associated
situations. The VSI comprises 15 items that are scored
between 0 and 6, with a total score between 0 (mini-
mum GSA) and 75 (maximum GSA). The VSI has
demonstrated high internal consistency (Chronbach’s a
= .90 - .92) [28] and most notably it has been shown to
be a key explanatory variable in predicting IBS diagnos-
tic status [24].
The Sheehan Disability Scales [47] assess symptom
induced disability in three domains: social, work, and
family from 0 (no disability) to 10 (severe disability),
with a total score between 0 and 30. The Sheehan Dis-
ability Scales show high internal consistency with
Chronbach’s a = 0.89 [48].
At 12-month follow-up patients were also asked what
type of health care, if any, they had utilized because of
IBS-symptoms since the treatment had ended.
Analysis
Main outcome continuous variables were analyzed in
SPSS 19 using a linear mixed effects model fitted with
full information maximum likelihood estimation (FIML)
[49]. Linear mixed models take into account the non-
independence of repeated-measures data and individual
heterogeneity by including random effects in the model.
The superior qualities regarding missing data as well as
increased power compared to the traditional repeated
measures ANOVA make mixed models the preferred
choice for longitudinal data analysis [50]. Linear mixed
models were used to examine the difference in rates of
change between the ICBT and waiting list from pre- to
post-treatment as the fixed effects interaction between
group and time. Model selection was determined analy-
tically by means of likelihood ratio tests and included
random intercepts. Error terms were held equal across
time and were not correlated. Mixed models were also
used to examine the effect of time between post-treat-
ment and 12-month follow-up for the ICBT group. Sen-
sitivity analyses were conducted by including treatment
seeking within the follow-up period as a covariate in the
analyses. These models used the same covariance struc-
tures as above.
All available data from all participants and measure-
ment points were used, which made this an intent-to-
treat analysis. Under the assumption of data missing at
random (MAR), FIML provides unbiased parameter esti-
mates compared to traditional methods (such as last
observation carried forward) even with a substantial pro-
portion of missing data [51]. FIML under the assump-
tion of MAR requires that observed variables that are
associated with the likelihood of data missingness are
included in the analysis [52]. Prior to conducting the
primary analysis, the missing data mechanism was
assessed by exploring the relationships between baseline
characteristics and the presence of missing data in the
sample.
A l lc o n f i d e n c ei n t e r v a l sa r eg i v e nw i t ha9 5 %m a r g i n .
Between-groups effect sizes were calculated as standar-
dized mean differences (Cohen’s d). Conservative esti-
mates of effect sizes were obtained by replacing missing
post-treatment data with pre-treatment data.
Cost-effectiveness analysis
The same methodological approach in the cost-effective-
ness analysis as in our previous study [17] was used to
make the results comparable across studies. Self-reports
from TIC-P were used to estimate the costs generated
by the participants. Medication costs were based on the
market price in Sweden. Costs of health care visits were
estimated using national tariffs in Sweden. Productivity
losses were based on the human capital approach, which
means that the value of reduced work productivity were
calculated using average gross earning [53]. Gross earn-
ings were estimated using the average salary in Sweden
by education level. Domestic losses were estimated at $
13.17 in accordance with our previous study [17] and
originally estimated by Smit et al. [54]. Costs were con-
verted to US$ using purchasing power parities for the
reference year 2010 [55]. The statistical cost data ana-
lyses were conducted using STATA 11/IC and SPSS 19
in three steps:
First, cost means between treatment and control
group at pre-treatment, post-treatment and at 12-month
follow-up were estimated. Similar to our previous study
[17], missing cost data was imputed in a last-observa-
tion-carried-forward manner, and all costs were extrapo-
lated to a 12-month period. ANCOVA with post-
treatment costs as dependent variables and pre-treat-
ment costs as covariates were conducted to assess
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treatment. Paired t-tests were used to test within-group
differences from pre- to post-treatment. Bootstrap repli-
cations (5000 replications) were used as we expected the
cost-data to be non-normally distributed [56].
Second, incremental cost-effectiveness ratio (ICER)
was estimated computing differences in costs and effects
between both conditions: (C(ICBT) - C(WL))/(E(ICBT) -
E(WL)). C refers to the pre-post cost differences and E
is the proportion of patients showing clinically signifi-
cant improvement in both conditions [53]. Similarly to
our previous cost-effectiveness study, clinically signifi-
cant improvement was defined as at least 50% symptom
reduction on the GSRS-IBS. This calculation was
repeated 5000 times (for each bootstrap sample) gener-
ating a scatter of simulated ICERs, which represents the
probability of the treatment being cost-effective. Figure
2 presents a scatterplot of the simulated ICERs. If a
majority of the ICERs appear in the southeast quadrant
of the figure, lower societal costs are achieved alongside
beneficial health gains. From a cost-effectiveness per-
spective, this is the most favorable outcome. ICERs
located in the northeast quad r a n ti n d i c a t et h a tb e t t e r
health gains are achieved with ICBT but to higher socie-
tal costs compared to no treatment. ICERs in the north-
west quadrant indicate that ICBT is inferior to no
treatment and results in higher societal costs. ICERs
located in the southwest quadrant indicate that ICBT is
associated with inferior health gains but produces low-
ered societal costs compared to no treatment.
T h i r d ,t h ee c o n o m i cl o n g - t e r mi m p a c tu s i n g1 2 -
month follow-up data was investigated. Since there was
no experimental control at 12-month follow-up, the
treatment group’s follow-up data was imputed and com-
pared with the post-treatment data of the control group.
This was done to test whether the extrapolation to a 12-
month period was a reliable analysis procedure.
Exploratory analysis
Clinical guidelines recommend that IBS patients should
be referred to psychological treatments if they show
anxiety, activity disruption or poor coping strategies
[7,57]. Since patients were recruited without taking
these factors into consideration, we tested whether low
levels of anxiety and poor coping strategies (as measured
by the VSI) or activity disruption (as measured by the
IBS-QOL and Sheehan Disability Scales) predicted low
treatment response (as measured by change score on
the GSRS-IBS from pre- to post-treatment). This was
done in two ways. First, median split was used to com-
pare the outcome between patients with scores above
the median and patients below the median on each of
the predictor variables, using t-tests. Second, each of the
predictor variables was correlated with the outcome,
while controlling for the pre-treatment value of GSRS-
IBS. These analyses were only performed on the ICBT
patients who participated in the post-treatment
assessment.
Results
Missing data
A total of 50 of the 61 randomized patients (82%) com-
pleted the post-treatment assessment, 23 of 30 (77%) in
t h eI C B Tg r o u pa n d2 7o f3 1( 8 7 % )i nt h ew a i t i n gl i s t .
Statistical tests of baseline characteristics showed that
patients with missing data tended to score higher on
GSRS-IBS (m = 48.1, SD = 12.5 vs. m = 40.9, SD = 11.2;
t60 =1 . 9 0 ,p = .06) than patients that completed the
post-treatment assessment. Within the ICBT condition,
patients that dropped out scored lower on the IBS-QOL
at pre-treatment (m = 52.2, SD = 26.1 vs. m = 72.0, SD
=1 7 . 1 ;t28 =2 . 3 6 ,p = .03). The pre-treatment scores of
GSRS-IBS and IBS-QOL were therefore included as can-
didate covariates in the analyses. If these variables signif-
icantly improved the model they were retained in the
final model. Of the 30 patients in the ICBT group, 20
(67%) completed the 12-month follow-up assessment.
One of these patients did not complete the post-treat-
ment assessment, but was included in the analysis of
change between post-treatment and follow-up resulting
in 24 patients in this analysis. Of these 24 patients 5
had missing data at either post-treatment or 12-month
follow-up. Because of the small groups, no analyses
were conducted to examine baseline differences between
the 5 patients with missing data and the 19 with com-
plete data.
Group comparisons
Results on the outcome measures at pre- and post-treat-
ment for both groups are displayed in Table 3 together
with coefficients for the fixed effects of group, time,
interaction effect of group and time, and retained pre-
Figure 2 Cost-effectiveness plane.
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Page 7 of 13treatment covariates. The mixed effect models demon-
strated significant interaction effects between group and
time on all outcome measures. The between groups
effect sizes at post-treatment were in the upper medium
range (d = 0.73-0.79) for all measures except the Shee-
han Disability Scales (d = 0.19). Replacing missing post-
treatment data with pre-treatment data yielded consider-
ably lower effect sizes on the GSRS-IBS (d = 0.23), IBS-
QOL (d =0 . 2 6 ) ,a n dV S I( d = 0.26) and a negligible
between-groups effect on Sheehan Disability Scales (d =
-0.05).
Follow-up
Table 3 displays the 12-month follow-up scores for the
ICBT group. The mixed effects models gave only one
significant effect of time, on the IBS-QOL (B =4 . 5 ,t20.1
=2 . 2 ,p = .04). This positive coefficient indicates further
improvement on the IBQ-QOL for the ICBT group dur-
ing the follow-up period while scores on the other out-
come measures were maintained. There were no
significant effects of time on the GSRS-IBS (B = -2.4,
t18.7 = -1.1, p = .27), VSI (B = -0.4, t19.5 = -0.26, p =
.80), or the Sheehan Disability Scales (B =- 1 . 4 ,t21.6 =
-1.2, p = .25).
Seven of the 20 patients (35%) reported further treat-
ment seeking because of IBS during the follow-up per-
iod, 6 had consulted a physician and 1 had sought
complementary treatment, none had sought further psy-
chological treatment. Sensitivity analysis did not indicate
any effect of further treatment seeking on maintenance
of improvement during the follow-up period.
Cost-effectiveness
Annual cost means are presented in Table 4. We found
no significant between-group interaction effects for any
cost domain, but a trend regarding work-cutback (F =
3.17, p = .08) favoring the ICBT condition was observed.
Paired t-tests showed a within-group cost reduction in
domestic loss (p = .01) and reduced medication costs (p
= .05) for the ICBT condition. The control group made
a significant increase in costs related to work-cutback (p
= .03). There were no within-group differences for the
treatment group between post-treatment and the 12-
month follow-up.
Table 3 Continuous outcome measures
Treatment Waiting list Effect size Mixed models
n m SD n m SD Cohen’s d (95% CI) Effect Bp
GSRS-IBS
Pre 30 44.6 11.1 31 39.8 12.0 Group 4.9 .12
Post 23 31.0 10.2 27 40.9 14.5 0.77 (0.19 - 1.34) Time 0.6 .63
FU 19 29.9 12.6 G×T -11.7 .001
IBS-QOL
Pre 30 67.4 20.9 31 76.1 18.8 Group -8.8 .09
Post 23 82.6 13.4 27 67.4 23.1 0.79 (0.20-1.35) Time -7.2 .001
FU 20 87.6 11.8 G×T 16.6 .001
VSI
Pre 30 32.5 18.0 31 27.5 16.3 Group 5.0 .22
Post 23 14.1 15.1 27 26.2 17.9 0.73 (0.14 - 1.29) Time -11.7 .01
FU 20 15.5 15.9 G×T -14.6 .001
COV 0.3 .03
Sheehan
Disability Scales
Pre 30 11.9 8.1 31 8.7 6.3 Group 3.2 .08
Post 23 6.4 6.7 27 7.8 7.6 0.19 (-0.37 - 0.75) Time -4.4 .01
FU 20 5.2 6.6 G×T -4.2 .002
COV 0.1 .04
Unstandardized (B) coefficients and their p-values are given for fixed in effects in linear mixed models using all data from pre-treatment and post-treatment and
all individuals (n = 61). The coefficient associated with the main effect of group denotes average score difference between the groups at the pre-treatment
assessment. The coefficient associated with the effect of time denotes the average change score from pre to post-treatment across both groups. The coefficient
associated with the effect of G × T (group × time) denotes the difference between groups in change score from pre- to post-treatment. COV is the effect of the
pre-treatment value of GSRS-IBS, as a retained covariate in the model, on the post-treatment value. Group0 = Treatment Group, Group1 = Waiting List, Time0 =
Pre-treatment, and Time1 = Post-treatment. Effect sizes are calculated as standardized mean difference (Cohen’s d) at post-treatment. GSRS-IBS: Gastrointestinal
symptom rating scale-IBS version. IBS-QOL: The Irritable Bowel Syndrome Quality of Life Instrument (IBS-QOL). VSI: The Visceral Sensitivity Index.
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Page 8 of 13The cost change for the treatment group was $17,808
- $15,014 = -$2,794 and the cost change in the control
group was $15,542 - $18,323 = $2,781. Clinically signifi-
cant improvement was demonstrated by 6 of 30 (20%)
patients in the treatment group and 2 of 31 (6%)
patients in the waiting list. The incremental cost effec-
tiveness ratio (ICER) was therefore (-2,794 - 2,781)/(0,20
- 0,06) = -39,821. This means that each significant clini-
cal improvement in IBS was associated with a societal
cost-reduction of $39,821. The cost-effectiveness plane
(Figure 2) gives a more detailed view of the data: 87% of
the ICERs were located in the southeast corner, indicat-
ing that ICBT was associated with societal cost reduc-
tions and also produced health gains compared to the
waiting list. There was an 8% probability of the treat-
ment producing superior health gains but to higher
societal costs (northeast quadrant). Only 4% and 1% of
the ICERs were located in the least favorable quadrants,
the southwest and northwest, respectively.
We repeated the analyses and imputed 12-month fol-
low-up data for the treatment group and compared it
with the waiting list’s post data. A majority (79%) of the
ICERs remained in the southeast corner, indicating
robustness of the results.
Prediction of outcome
The VSI, IBS-QOL and Sheehan Disability Scales were
used to test if low values predicted low improvement on
the GSRS-IBS. Using median split the difference in out-
come between high and low scorers on the IBS-QOL,
VSI, and SDS were not significant (p = .11 - .23). When
the predictors were correlated with the symptom
improvement score, controlling for GSRS-IBS baseline
score, none significantly predicted the change in GSRS-
IBS (p = .12 - .50, r = .15 - .34).
Discussion
The aim of this study was to evaluate the acceptability,
effectiveness, and cost-effectiveness of a treatment pre-
viously demonstrated to be efficacious in treating a self-
selected sample of IBS patients [14,15]. Patients in this
study were consecutively recruited from a gastroentero-
logical clinic and were randomized to ICBT or a waiting
list. There was considerable dropout in the study, with
only 77% of the ICBT patients participating in the post-
treatment assessment and 43% completing the treat-
ment. Compared to the waiting list, the ICBT partici-
pants experienced reductions in IBS symptoms, anxiety
related to IBS symptoms, as well as improvements in
IBS-related quality of life. The effects were more pro-
nounced on the IBS-specific measures than the general
measure of daily functioning, probably owing to low
pre-treatment values on this measure. Despite the large
dropout from the ICBT condition, the treatment pro-
duced societal cost-savings compared to the waiting list.
Additionally, the cost-savings offset the treatment costs
both in short- and long-term.
In our previous trial where we used a waiting list as
comparison group, the between-groups effect on GSRS-
IBS (d = 1.21) [14] was larger than the between-groups
effect observed in this trial (d = 0.77). Using conserva-
tive estimates, by replacing the missing data with pre-
treatment assessments, the between-group effect sizes
were even lower. Because of the large proportion of
Table 4 Mean annual costs
Pre-treament Post-treatment Follow-up
Treatment Waiting list Treatment Waiting list Treatment
m (se) m (se) m (se) m (se) m (se)
Direct medical costs 2487 (633) 2115 (689) 1148 (301) 1453 (417) 1868 (566)
Health care visits 2455 (634) 2082 (687) 1405 (374) 1412 (413) 2284 (706)
Medications 33 (8) 33 (11) 21 (8) 42 (18) 37 (17)
Direct non-medical costs 504 (265) 88 (42) 150 (105) 338 (243) 405 (177)
Indirect non-medical costs 14817 (3554) 13440 (2852) 12729 (3103) 16233 (3124) 12437 (3134)
Unemployment 10204 (3435) 7054 (2937) 8747 (3248) 8465 (3155) 8747 (3248)
Sick-leave 3492 (1531) 5547 (1439) 3028 (940) 6295 (1698) 2816 (900)
Work cutback 376 (138) 211 (78) 515 (233) 998 (287) 426 (167)
Domestic 744 (182) 528 (157) 440 (152) 475 (114) 448 (140)
Total (excl. intervention costs) 17808 (3866) 15542 (3029) 14306 (3131) 18025 (3367) 15163 (2368)
Intervention costs 709 (78) 298 (26) 709 (78)
Total (incl. intervention costs) 17808 (3866) 15542 (3029) 15014 (3112) 18323 (3370) 15871 (3343)
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Page 9 of 13missing data and the fact that patients that dropped out
were more impaired than the patients that stayed in the
trial, the conservative effect sizes are highly influenced
by the dropouts. Still, they indicate that for the whole
randomized sample, ICBT was clearly less effective than
in our previous studies.
The acceptability of ICBT, as measured by the propor-
t i o n so fp a t i e n t si nt h eI C B Tg r o u pt h a ts t a y e di nt h e
study (77%) and completed treatment (43%), also dif-
fered between this study and our previous studies. In
these, 90%-99% of participants completed the post-treat-
ment assessment [14,15] and 69% of the participants
completed all five treatment steps [14]. In addition,
while 14 of 75 included patients (19%) withdrew from
this study before randomization, 0%-3% withdrew from
our previous studies after inclusion [14,15].
These differences in effectiveness and acceptability are
likely linked to the differences in recruitment method.
In our study of group CBT for IBS [18], gastroenterolo-
gists at several clinics referred patients that they judged
would benefit from treatment and in our previous stu-
dies of ICBT [14,15], patients were self-referred. It
would be reasonable to assume that the patients in this
study, who were offered to participate simply because
they visited a gastroenterological clinic, would be less
motivated to engage in treatment. Exposure treatment
demands a lot from patients and ICBT also requires
them to work independently with planning and conduct-
ing the exposure exercises. This may have been too
challenging for some patients who might not have
applied for the study if we would have used self-referral
as recruitment method.
According to clinical guidelines, IBS patients with
anxiety, poor coping strategies, or functional impairment
should be offered psychological treatment [7,57]. Indeed,
a recent study showed that improvement after CBT for
IBS was mediated through change in avoidance beha-
viors and negative thoughts about symptoms [58] and
that less adaptive IBS behaviors predicted good outcome
[59]. However, in this study we did not observe this
association. It seems that patients who displayed com-
parably low levels of avoidance still experienced symp-
tom improvement by changing these behaviors. The
study does suggest that large impairment and severe
symptoms may be predictive of treatment dropout.
However, our previous studies point in another direc-
tion. The average pre-treatment scores on GSRS-IBS
and IBS-QOL were markedly higher in those studies
than in this study, while participants showed larger
improvement and treatment adherence [14,15]. This is
in accordance with research demonstrating that IBS
patients recruited through the internet are more
impaired than clinical patients [60]. Thus, it seems that
the method of recruitment is more predictive of
treatment outcome than symptom severity and level of
impairment. More research is needed to establish what
minimum level of avoidance behaviors that is required
to benefit from a treatment that targets these behaviors.
Other types of psychological treatments for IBS, such as
hypnosis, self-management, psychodynamic therapy, and
cognitive therapy, may target other mechanisms and
require other selection criteria.
An important limitation in this study is our use of a
waiting list as a comparison group. Although this prac-
tice is common in trials of psychological treatments it
has been criticized as it does not control for non-speci-
fic factors such as expectancy of improvement and
attention from a caregiver [61]. Several trials of psycho-
logical treatments for IBS have failed to show differen-
tial effects on symptoms when using attention control
conditions [32,62-64], and a recent study showed that
IBS patients even respond to open-label placebo [65].
These studies underline the need for an active control
group when evaluating psychological treatments for IBS.
However, ICBT did show superiority to an active con-
trol in our previous study where 195 self-referred IBS
patients were randomized to ICBT or internet-delivered
stress management [15].
Another limitation is that although our aim was to
evaluate the treatment for a clinical sample, it was not
carried out within a clinical context. Patients had to par-
ticipate in an extensive pre-treatment assessment,
including a psychiatric evaluation and four weeks of
weekly symptom ratings, and were then randomized to
treatment or waiting list. These circumstances are sel-
dom part of clinical care and may have contributed to
the high dropout rate. We did not include patients who
had severe diarrhea and were therefore judged to
require prescription of psychotropic drugs. Eleven of the
131 eligible patients (8%) were excluded from the study
for this reason. It would have been preferable to pre-
scribe the drug and after evaluation of its effects possi-
bly offer these patients participation in the study.
However, for practical reaso n st h i sw a sn o tp o s s i b l e ,a s
it would have altered the inclusion procedure and time
frame. This further limits the generalizability of the
results regarding these patients.
The cost-effectiveness analysis also has some limita-
tions. We did not use the actual salary of the patients
but estimated them based on educational levels. This
produces errors in the estimated costs but should not
affect the ICER as it relies on the randomization.
Further, we estimated the cost of treatment based only
on the amount of therapist time. This estimation does
not include the cost of writing the treatment manual or
developing the web platform used for delivering the
ICBT, nor does it include the overhead costs of running
an ICBT treatment clinic.
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This study shows that ICBT for IBS, based on expo-
sure principles, can be an effective treatment option
for some patients at a tertiary care clinic. Patients with
large impairment and severe symptoms may be less
able or willing to engage in ICBT. From a cost-effec-
tiveness perspective, offering ICBT to clinical patients
seems to lead to considerable societal savings com-
pared to no further treatment after regular clinical
care, even with large dropout rates and low treatment
adherence. For patients that benefit from the treat-
ment, improvements are maintained over a 12-month
period. More research is needed to clarify for which
patients ICBT based on exposure and mindfulness
exercises is best suited.
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